Karineh Kazazian

Dr. Karineh Kazazian

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2026 in European Journal of Human Genetics
Verified
Journal Article
Open access
KFKirsten M. Farncombe
Kirsten M. Farncombe
JSJulia A. Sobotka
Julia A. Sobotka
MAMelyssa Aronson
Melyssa Aronson
MBMark Basik
Mark Basik
YBYvonne Bombard
Yvonne Bombard
RKRaymond Kim
Raymond Kim
Individuals with hereditary cancer syndromes are born with germline genetic variants that significantly increase their lifetime risk of developing multiple cancers. Cancer rates and overall mortality can be reduced with intensive surveillance to facilitate early cancer detection. However, participating in diagnostic imaging and endoscopy surveillance programs is often time-consuming, overwhelming, inconvenient, and anxiety-inducing. To improve this, multi-cancer early detection tests are being developed using cell-free DNA (cfDNA) sequencing analysis to detect cancers with more sensitivity than conventional screening methods. Our community (the CHARM consortium: Cell-free DNA in Hereditary And high-Risk Malignancies) has been exploring the use of cfDNA sequencing in hereditary cancer, and has launched the CHARM2 prospective randomized controlled trial, which is enrolling 1000 participants with Hereditary Breast and Ovarian Cancer, Lynch syndrome, Li-Fraumeni syndrome, Neurofibromatosis type 1 and Hereditary Diffuse Gastric Cancer to improve equitable access, early detection and surveillance for high-risk individuals. All participants will have screening as per conventional syndrome-specific surveillance recommendations. Half the participants (experimental cohort) will also have cfDNA analysis at least three times a year, with abnormal results triggering dedicated clinical imaging and diagnostic evaluation, and heightened surveillance. Vetted by our patient advisors, validated patient-reported outcome and experience measures assessing participant psychosocial outcomes, engagement, and test preferences will be administered to both arms. Our goal is to inform if and how cfDNA analysis could be implemented into routine clinical care and offer a path to equitable and more convenient cancer screening for all high-risk Canadians.

23 June 2026 in Cancer Gene Therapy
Verified
Journal Article
Closed access
DNDeanna Ng
Deanna Ng
KKKarineh Kazazian
Karineh Kazazian
KLKiera Lee
Kiera Lee
YLYi Qing Lu
Yi Qing Lu
AAAiman Ali
Aiman Ali
MMMarco Magalhaes
Marco Magalhaes

18 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DNDeanna Ng
Deanna Ng
KKKarineh Kazazian
Karineh Kazazian
KLKiera Lee
Kiera Lee
YLYi Qing Lu
Yi Qing Lu
AAAiman Ali
Aiman Ali
MMMarco Magalhaes
Marco Magalhaes
Epithelial cancers such as stomach and ovary cancer tend to metastasize to the peritoneum, often leading to intractable disease and poor survival. Currently, the mechanisms that enable gastric cancer cells to penetrate the mesothelium, and to implant, invade, and survive in the peritoneal niche are poorly understood. To investigate these mechanisms, we developed a novel human peritoneal explant model. Briefly, fresh peritoneal tissue samples from abdominal surgery patients were cultured on top of a layer of GFP-labeled human gastric adenocarcinoma cells (AGS); 2% of these cells implanted into the peritoneum. The transcriptomic profile of the implanted AGS cells was compared to the profile of AGS cells that failed to implant using RNA sequencing. Differentially expressed genes were enriched significantly (fold change>2) for genes that enable cell adhesion, motility, and membrane depolarization. We compared this list of genes with a previously identified peritoneal metastasis whole exome sequencing dataset (SRP043661). Upon further analysis based on subcellular localization, cell adhesion and cytoskeletal organization, we found nine core “peritoneal implantation” genes. We functionally validated these genes with CRISPR knockout and assessed peritoneal implantation and invasion using the human peritoneal explant model described above. From these data we identified ADAM12 as a key player of peritoneal metastasis. Knock out of ADAM12 significantly impaired peritoneal metastasis in vivo and ex vivo . Exploration of three publicly available independent datasets indicated that ADAM12 is indeed clinically relevant in peritoneal metastasis. To explore the role of ITGAβ1 in mediating cell-matrix interactions in the presence of ADAM12, we performed ITGAβ1 pull-down assays followed by mass spectrometry analysis in ADAM12 WT cells. ADAM12 KO cells show a marked disruption of the ITGAβ1 interactome in GCa cells. Key cytoskeletal proteins such as MYH14, MYH10, MYH9, ACTA2, SPTN1 and TPM1–TPM4 were found to be interactors with ITGAβ1 in ADAM12 WT cells but not ADAM12 KO cells. Our approach and the new data identify a distinct peritoneal metastasis gene set that facilitates implantation and invasion of gastric cancer cells within the peritoneum. Disruption of these pathways with peritoneal-directed therapies has the potential to improve survival in patients with high-risk primary gastric cancer.

8 May 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
SCSami Ahmed Chadi
Sami Ahmed Chadi
KKKarineh Kazazian
Karineh Kazazian
PSPaul Savage
Paul Savage
CBChristine Brezden-Masley
Christine Brezden-Masley
RBRonald Burkes
Ronald Burkes
CSCarol J. Swallow
Carol J. Swallow
Advances in surgical techniques, radiographic imaging capabilities, radiotherapy, and chemotherapy have led to improved outcomes for patients with rectal adenocarcinoma. Treatment strategies have correspondingly evolved, as seen with total neoadjuvant therapy (TNT) and organ preservation approaches. TNT is a treatment strategy for primary, non-metastatic, resectable mismatch repair proficient rectal cancer where the intent is to administer all appropriate adjuvant therapy in the preoperative phase, including both systemic therapy and chemoradiotherapy/radiotherapy. In this setting, TNT is increasingly administered for the purposes of maximizing tumour response to facilitate resection, improving treatment compliance, thus increasing the likelihood of a complete response to allow for organ preservation and for the possibility of improving survival. While several recent randomized controlled trials have described the role of TNT in the contemporary treatment of rectal cancer, there is significant heterogeneity in sequencing of treatments, dosing, allowance for non-operative management, and the potential for over-treatment. Our objective here was to incorporate current evidence to develop a consensus-based institutional treatment algorithm to be used in the ambulatory and multidisciplinary team setting for the treatment of stage I–III rectal cancer.

6 July 2026 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
DNDeanna Ng
Deanna Ng
KKKarineh Kazazian
Karineh Kazazian
KLKiera Lee
Kiera Lee
YLYi Qing Lu
Yi Qing Lu
AAAiman Ali
Aiman Ali
MMMarco Magalhaes
Marco Magalhaes

11 December 2025 in Innovative Surgical Trends
Verified
Journal Article
Open access
PDF file
KKKyung Young Kim
Kyung Young Kim
AMAlexandre Mikhail
Alexandre Mikhail
SCSami Chadi
Sami Chadi
KKKarineh Kazazian
Karineh Kazazian
Purpose: Laparoscopic cholecystectomy (LC) in patients with situs inversus totalis (SIT) is technically challenging due to the reversed anatomical orientation of the thoracoabdominal organs, which can increase operative complexity and the risk of complications. Although the incidence of cholelithiasis and cholecystitis in SIT is similar to the general population, altered anatomy may lead to diagnostic and intraoperative uncertainty. We describe LC in a patient with SIT using intraoperative indocyanine green (ICG) fluorescence cholangiography to guide the identification of biliary structures. Methods: Preoperative ultrasound, computed tomography, and magnetic resonance imaging are used to delineate anatomy and exclude biliary duct dilation or biliary anomalies. ICG (0.5 mL of 2.5 mg/mL) is administered intravenously one hour before surgery. A mirror-image port configuration is employed centered on the left hemiabdomen, with the surgeon standing on the patient’s right and the assistant on the left. During surgery, ICG fluorescence cholangiography is utilized intraoperatively to enhance visualization of the biliary anatomy and facilitate attainment of the critical view of safety. Results: LC was successfully performed without complications. ICG imaging enabled clear identification of the cystic duct and common bile duct, mitigating the risks associated with anatomical variation in SIT. Conclusion: LC in patients with SIT is rarely described and technically demanding due to reversed intra-abdominal anatomy. ICG fluorescence cholangiography is an innovative tool and valuable adjunct that improves biliary visualization and may enhance safety in complex anatomical settings.